Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

per Pollack, M H, Betof, A, Dearden, H, Rapazzo, K, Valentine, I, Brohl, A S, Ancell, K K, Long, G V, Menzies, A M, Eroglu, Z, Johnson, D B, Shoushtari, A N
Publicat a Ann Oncol (2018)